Guidelines for Ocular Surface Medication Stewardship

Abstract

Ocular surface diseases are a significant source of morbidity worldwide, necessitating judicious use of medications to optimize patient outcomes while minimizing adverse effects and resistance. Medication stewardship in ophthalmology, particularly for ocular surface conditions, is an emerging paradigm that aligns with broader antimicrobial stewardship principles and rational pharmacotherapy. This review synthesizes current guidelines and evidence pertinent to ocular surface medication stewardship, encompassing disease burden, pathophysiology, risk stratification, clinical manifestations, diagnostic strategies, therapeutic approaches, recent advances, and formal recommendations. Emphasis is placed on individualized, evidence-based care and strategies to mitigate unnecessary medication exposure, promote patient safety, and foster sustainable clinical practices.

Introduction

The ocular surface comprises a complex anatomical and functional unit, including the cornea, conjunctiva, tear film, and associated glands. Diseases impacting this interface, such as dry eye disease (DED), allergic conjunctivitis, and infectious keratitis, are prevalent and often require pharmacologic intervention. However, inappropriate or excessive use of topical medications can precipitate complications, including toxicity, resistance, and ocular surface deterioration. Ocular surface medication stewardship (OSMS) seeks to balance therapeutic efficacy with safety, resource utilization, and long-term patient welfare. This article delineates the framework and practical application of OSMS based on contemporary scientific literature and expert guidelines.

Epidemiology / Disease Burden

Ocular surface disorders represent a substantial public health concern, affecting up to 30% of adults globally, with dry eye disease being the most prevalent entity. The aging population, rising screen use, and environmental exposures contribute to increasing incidence and prevalence. Infectious causes, particularly bacterial and viral conjunctivitis, account for millions of outpatient visits annually. The economic burden is significant, encompassing direct healthcare costs and productivity loss. Consequently, rationalizing medication use through stewardship programs has the potential to impact not only individual patient outcomes but also broader healthcare systems.

Pathophysiology

The pathophysiology of ocular surface diseases is heterogeneous. In DED, tear film instability, hyperosmolarity, and inflammation play central roles, often perpetuated by environmental and iatrogenic factors. Allergic conjunctivitis results from IgE-mediated mast cell activation, leading to cytokine release and vascular permeability. Infectious etiologies involve microbial invasion, host immune response, and, in some cases, biofilm formation. Medication-induced toxicity often arises from preservative exposure, chronic inflammation, and disruption of the epithelial barrier. Understanding these mechanisms is critical for selecting targeted therapies and minimizing collateral tissue damage.

Risk Factors

Identifying modifiable and non-modifiable risk factors is central to stewardship. Non-modifiable risks include age, genetic predisposition, and underlying systemic diseases such as autoimmune disorders. Modifiable risks encompass contact lens use, environmental exposures (e.g., low humidity, pollutants), medication overuse, and poor ocular hygiene. Polypharmacy, particularly with preserved topical agents, increases susceptibility to toxicity. Recognizing these factors enables individualized risk stratification and targeted interventions to optimize medication use.

Clinical Features

Ocular surface diseases present with a spectrum of symptoms, including foreign body sensation, burning, photophobia, redness, discharge, and fluctuating vision. Clinical examination may reveal conjunctival injection, corneal staining, lid margin disease, and tear film abnormalities. Chronic or relapsing cases often reflect inappropriate or excessive medication use, underscoring the importance of stewardship in diagnosis and management. Detailed history-taking, including prior and current medications, is essential for identifying iatrogenic components.

Diagnosis

Diagnosis relies on a combination of clinical assessment and adjunctive testing. Slit-lamp biomicroscopy, tear film breakup time, Schirmer test, and ocular surface staining are standard modalities. Microbiological cultures, polymerase chain reaction (PCR), and impression cytology may be indicated for infectious or refractory cases. Stewardship principles advocate for judicious use of diagnostics, avoiding unnecessary or redundant investigations while ensuring accurate etiological identification to guide therapy.

Treatment & Management

Management is etiology-specific but universally emphasizes minimizing unnecessary pharmacologic exposure. First-line therapy for DED includes tear substitutes and environmental modifications, reserving anti-inflammatory agents for moderate-to-severe cases. Infectious conjunctivitis often warrants observation or narrow-spectrum antibiotics based on culture results, avoiding empirical broad-spectrum agents. Allergic disease management prioritizes allergen avoidance and targeted antihistamines or mast cell stabilizers. Polypharmacy and preservative burden should be minimized, favoring preservative-free formulations when long-term use is anticipated. Education on adherence, application techniques, and the importance of follow-up are integral to stewardship.

Recent Advances / Emerging Therapies

Recent developments in ocular surface therapeutics include novel anti-inflammatory agents (e.g., lifitegrast, cyclosporine A nanomicellar formulations), biologics for refractory cases, and microbiome-based interventions. Advances in diagnostic technology, such as point-of-care testing for tear osmolarity and rapid pathogen identification, support more precise, stewardship-aligned approaches. Artificial intelligence and tele-ophthalmology platforms are emerging as tools for remote monitoring and medication optimization. These innovations promise to enhance efficacy, reduce adverse effects, and advance the goals of OSMS.

Guideline Recommendations

International and national guidelines increasingly emphasize medication stewardship principles in ocular surface disease management. Key recommendations include: (1) utilizing the minimum effective dose and duration; (2) prioritizing non-pharmacologic interventions where feasible; (3) reserving antibiotics and corticosteroids for clear indications; (4) minimizing preservative exposure, especially in chronic disease; (5) engaging patients in shared decision-making and education; and (6) regular review of medication necessity and regimen simplification. Institutional programs, formulary controls, and audit-feedback mechanisms are advocated to standardize stewardship practices across clinical settings.

Conclusion

Ocular surface medication stewardship is an essential strategy to optimize therapeutic outcomes, prevent resistance, and safeguard ocular health. By integrating evidence-based guidelines, pathophysiological insights, and individualized care, clinicians can navigate the complexities of ocular surface disease pharmacotherapy. Ongoing research, technological innovation, and interdisciplinary collaboration will continue to refine and advance stewardship frameworks, ultimately improving patient care and public health outcomes in ophthalmology.